Pakistan's anti-polio drive suffers a blow after a northern enclave reports first case in 7 years
The virus was detected in a child from the district of Diamer in the Gilgit-Baltistan region, according to the country's polio eradication program.
Pakistan and neighboring Afghanistan remain the only two countries where the spread of the wild polio virus has not been stopped, according to the World Health Organization. There are ongoing outbreaks of polio linked to the oral vaccine in 10 other countries, mostly in Africa.
The new case was reported after Pakistan on Sunday wrapped up its third nationwide polio vaccination drive of the year, aiming to immunize 45 million children.
Mohammad Iqbal, a director at the polio program in the northwest, said local health officials were still trying to determine how the poliovirus that was found in the southern port city of Karachi had infected the child in Diamer.
During the summer season, thousands of tourists from Karachi and elsewhere visit tourist resorts in Gilgit-Baltistan.
Pakistan's polio eradication program has been running anti-polio campaigns for years, though health workers and the police assigned to protect them are often targeted by militants who falsely claim the vaccination campaigns are a Western conspiracy to sterilize children.
Since the 1990s, attacks on polio vaccination teams have killed more than 200 workers and security personnel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
2 Stocks to Buy on the Dip and Hold for 10 Years
Novo Nordisk's shares look attractive after a terrible performance over the past 12 months. DexCom has significant room to grow in its core market, despite disappointing results last year. 10 stocks we like better than Novo Nordisk › One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities. Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM). Although these two corporations have encountered significant headwinds since last year, they could deliver market-beating returns to investors who initiate positions today and stick with them for at least a decade. Novo Nordisk is coming off clinical setbacks and unimpressive financial results, at least by its lofty standards. The stock has significantly underperformed the market over the trailing-12-month period. But after this beating, the company's shares look attractive. Here are several reasons why. First, although Novo Nordisk's eternal rival, Eli Lilly, appears to be taking the lead in the fast-growing weight management market, the former still has excellent prospects in this rapidly expanding therapeutic area. Novo Nordisk's Wegovy continues to grow its sales at a good clip, and the company is awaiting approval from the U.S. Food and Drug Administration for an oral formulation of this popular medicine. Further, Novo Nordisk has promising internally developed pipeline candidates, such as amycretin, which recently entered phase 3 studies. The Denmark-based drugmaker has also enhanced its pipeline in this area, thanks to licensing deals and acquisitions. Second, Novo Nordisk has been working on diversifying its lineup and currently has promising pipeline candidates outside of its core treatment areas of diabetes and obesity. Novo Nordisk is developing medicines for conditions including hemophilia, Parkinson's disease, sickle cell disease, Alzheimer's disease, and others. Third, after being southbound for the past 12 months, Novo Nordisk's shares look reasonably valued. The company's forward price-to-earnings ratio is 16.8, compared to the 16.3 average for the healthcare industry. Novo Nordisk's financial results over the past year have been terrific by industry standards, but not quite what the market expected. That may have justified the sell-off, but at current levels, the stock looks attractive. Finally, Novo Nordisk is a solid dividend-paying company. It has increased its annual dividend per share by almost 284% over the past decade, while offering a forward yield of 2.3%. That's not exceptional, but it's above the S&P 500 index's average of 1.3%. Novo Nordisk is well-positioned to bounce back and deliver strong returns in the next decade as it rides weight management (and other) tailwinds. DexCom is a leading diabetes-focused medical device company. It develops continuous glucose monitoring (CGM) systems that help diabetics with constant blood sugar level measurements. DexCom has been successful thanks to the increased adoption of this innovative technology. Unlike blood glucose meters that are manually operated, use pesky and painful fingersticks, and can only tell a person's sugar level at one point in time, CGM devices are constantly monitoring things and automatically make measurements as often as every five minutes. Rrevenue and earnings have grown rapidly over the past decade, but the company hit a speed bump last year when its top-line growth slowed considerably, partly due to higher-than-expected rebates in the U.S., resulting in lower revenue per patient. That said, these are short-term issues that do little to impact the company's long-term prospects. And on that front, there are still plenty of reasons to be excited about DexCom's future. Consider that the company has ample room to grow, even in the U.S., a country that enjoys higher CGM penetration than most others. However, as DexCom has consistently pointed out, the population of patients who use CGM continues to lag behind those who are eligible for third-party coverage -- in other words, many people could obtain the technology paid for by insurers but have not yet opted in. Further, there is a vast worldwide opportunity, since only a tiny percentage of the diabetics in the world use CGM technology. Though many are in countries where DexCom does not do business, the company has generally increased its addressable market by entering new geographies. In the next 10 years, expect the company to do the same while benefiting from greater insurance coverage for CGM -- third-party payers, including governments, have been more willing to foot the bill because of the technology's benefits. All that should lead to consistent revenue and earnings growth for the medical device specialist. The stock has crushed the market in the past decade using this formula. In my view, it is well-positioned to do the same through 2035. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Stocks to Buy on the Dip and Hold for 10 Years was originally published by The Motley Fool
Health Line
2 hours ago
- Health Line
Rob Lowe Wants More People to Join Cancer Clinical Trials. Here's Why
Rob Lowe shares how three generations of women in his family passed away from breast cancer. The acclaimed actor has partnered with Eli Lilly to spread awareness about the benefits of cancer clinical trials. Lowe's grandmother benefited from participating in two clinical trials for breast cancer. Iconic actor Rob Lowe credits his grandmother, Mim, for his love of reading. 'My earliest memories are her reading me my favorite book, 'Peter Rabbit,' while she sipped her Sanka,' he told Healthline. 'I always wanted to have my own coffee, so she would make me a cup of milk and then put a little drop of Sanka in it so it would look like coffee.' When he was 10 years old, Mim was diagnosed with breast cancer, the same disease her mother had endured. 'It was almost a death sentence,' Lowe said. Following her diagnosis, Mim underwent a bilateral mastectomy, the standard of care at the time, which can significantly impact quality of life. While double or bilateral mastectomy rates have declined in recent years, some people still require the surgery. After a cancer recurrence, Mim entered a clinical trial, which Lowe said extended her life. Years later, she participated in a second clinical trial. 'Both times had tremendous, tremendous success, and it was a very pivotal moment in my upbringing that I always remember,' he said. Following his grandmother's diagnosis, Lowe's mother was also diagnosed with breast cancer. He said her standard of care was an improvement compared to his grandmother's. 'There are amazing advances in medicine, particularly breast cancer, and what I've seen going through this three times is tremendous enhancements,' Lowe said, noting the impact clinical trials have had on cancer treatments. Now, Lowe wants more people to participate in clinical trials. Only around 7% of U.S. cancer patients join clinical trials, limiting their access to potential breakthroughs and delaying new medications from helping others. In honor of the three generations of women he lost to breast cancer, Lowe teamed up with Eli Lilly to bring awareness to the urgent need for more people to participate in cancer clinical trials. 'I thought this was a great way to remember and keep my grandma Mim's memory alive,' he said. Clinical trials offer hope to people with cancer. For instance, a new breast cancer vaccine is showing effectiveness in clinical trials at preventing and treating breast cancer. The vaccine works by training the immune system to recognize and eliminate cancerous cells before they develop into invasive tumors. 'Participating in a trial can provide access to cutting-edge drugs that are not yet on the market, improve quality of life, and advance science. The trials of today are the treatments of tomorrow,' Davendra Sohal, MD, associate director for Clinical Research at the University of Cincinnati Cancer Center, told Healthline. Clinical trials are used for all types and stages of breast cancer. People can join any phase of a trial if they meet the criteria, which is based on multiple factors, including type of disease, age, medical history, and current medical condition. However, barriers to clinical trials prevent many people from enrolling. These include: certain beliefs or lack of trust distance to trial sites insufficient health insurance coverage language barriers immigration status In addition to barriers, new treatments developed in clinical trials face a long road before they're approved for use in the real world. 'New treatments are studied for lengthy periods of time, typically years, before they receive FDA approval,' Irene M. Kang, MD, medical director of women's oncology at City of Hope Orange County, told Healthline. 'This is why clinical trials are critical for studying new drugs, medical devices, products, and additional treatments before they may become standard of care.' If you want to know more about clinical trials, Lowe encourages you to ask your doctor. '[There's] so much hope out there, and it's not an end-of-the-road ask. If it's the beginning of the road, ask your doctor,' he said. Healthline spoke with Lowe to learn more about the women in his life who were diagnosed with breast cancer and his passion for participating in clinical trials. This interview has been edited and condensed for clarity and length. Did your grandmother's experience with clinical trials impact your views on medicine? Lowe: Yes. Particularly as she got into the second one, where I was much older and really able to understand it more clearly. We were very fortunate to have the experience of watching the miracle of progress in medicine unfold in real time with real results. Obviously, not everyone has that result, but we did, and that's where I've gotten my lifelong interest in cancer patient advocacy from, because of our experience. I remember the treatments that were horrifying for my grandma… and then with my mother, it was a completely different experience a decade later. The exponential rate of new technology is truly a marvel, and now with AI, it will be more unbelievable. How did having three women in your family die from breast cancer affect you? Lowe: The new [genetic] tests were not available for them. My brother Chad has three daughters, so they will be getting the test, and I will make sure of it. Family history is a big deal. Know your family history. Information and asking questions are as critical as any treatment you're going to get. Be diligent. What would you say to those who are wary of clinical trials? Lowe: My number one thing is that all patients have to advocate for themselves. It is the number one game changer in the path you have ahead of you — your ability to advocate, to ask questions, to champion, and guide your own recovery is critical. Doctors are only as good as the information they get and the questions that they're asked. One of them that a lot of people don't ask is: Is there a clinical trial that can be helpful for me? It's very simple. Less than 7% of patients do it. That number needs to be much, much, much higher. I would also add that I think one of the reasons that there's some [hesitation] is that I think people feel like 'well, if I'm in a clinical trial, maybe I'm going to get a placebo and I actually want treatment.' Well, in cancer clinical trials, you get the standard of care. You're not going to not get the standard of care. You may get a cutting-edge new care in addition, and to me, that's a no-brainer. Is it rewarding to work with Eli Lilly to spread awareness about something so personal? Lowe: I do find it really rewarding and, more than anything, inspiring. You get inspired by both the patient's journey, which is always a journey of courage, and by having a front-row seat with a company like Lilly, where you see the strides being made that make me so hopeful for the future; it's something I get a lot out of personally. What inspires you to talk about health? Lowe: One's health is the great equalizer, as we all know, and nothing reminds you of your humanity more than the frailty of our health and the importance that we all have of doing the best that we can for ourselves in that area. It does keep you connected to your fellow human beings. Have your views on health changed as you've gotten older? Lowe: I've been fortunate that I've always kept it [a priority] since my early 20s when I stopped drinking and had a very healthy path of recovery and mental healthcare. I was kind of early to the party and stayed the course, and it's been unbelievably beneficial to me as I've gotten older. [Now, I] offer that advice, as I can, even to my sons, who are in their early 30s.
Wall Street Journal
3 hours ago
- Wall Street Journal
How Healthcare Cuts in the ‘Big, Beautiful Bill' Will Affect Americans
The passage of President Trump's 'one big, beautiful bill' has left some hospitals, doctors and patient-advocacy groups reeling. Millions of people will lose health-insurance coverage, and struggling hospitals across the country may have to close, lay off staff or shut down some services, they say. States will also face difficult budget choices as federal funds are reduced. 'The magnitude of these reductions—and the number of individuals who will lose health coverage—cannot be simply dismissed as waste, fraud, and abuse,' Rick Pollack, president of the American Hospital Association, said after the House narrowly passed the bill. Trump signed the bill into law on Friday, Independence Day.
